Vitamin D and Vascular Calcification in Chronic Kidney Disease

Mariano Rodriguez  Julio Manuel Martinez-Moreno  M. Encarnación Rodriguez-Ortiz  Juan R. Muñoz-Castañeda  Yolanda Almaden

Unidad de Investigación, Servicio de Nefrología, Red in ren, Instituto Maimónides de Investigación Biomédica de Córdoba, Departamento de Medicina, Hospital Universitario Reina Sofia, Córdoba, España

Key Words
Vascular calcification · Vitamin D · Vitamin D analogs · Phosphate · Calcium · Chronic kidney disease

Abstract
Vascular calcification is common in patients with chronic kidney disease (CKD) and contributes to the increased rate of cardiovascular morbidity and mortality. The mechanisms regulating vascular calcification are under investigation; it is accepted that vascular calcification is an active and complex process involving many factors that promote or inhibit calcification. Vascular smooth muscle cells undergo transformation into osteogenic cells. This transformation is being stimulated by high phosphate, and more recently the role of the calcium phosphate nanocrystals has gained attention. Experimental models of uremia and in vitro studies have shown that an excess of calcitriol accelerates vascular calcification. However, observational studies suggest that vitamin D provides a survival advantage for patients with CKD. Experimental work shows that for similar serum concentrations of calcium and phosphate paricalcitol produces less vascular calcification than calcitriol suggesting a differential effect at the cellular level. Important issues regarding the role of vitamin D compounds on vascular calcification will be commented in this review.

Vascular Calcifications in Chronic Kidney Disease

Vascular calcification is frequent in patients with chronic kidney disease (CKD). The presence and extent of vascular calcifications are predictors of cardiovascular and all-cause mortality in stable end-stage renal disease patients on hemodialysis [1–4]. It is more likely to find vascular calcification in older diabetic patients with a long time on dialysis and abnormalities of bone and mineral metabolism [5]. Therapeutic strategies to control secondary hyperparathyroidism, such as calcium-based phosphate binders and high doses of vitamin D, may contribute to the development of vascular calcifications [6].

The effects of vitamin D on vascular health are complex and highly dependent on the dose being administered [7]. Vitamin D compounds play a role in the regulation of many cell functions in the body; they are essential for normal bone and mineral metabolism, proliferation and differentiation of various cell types, and the immune response [8]. Undesirable effects of vitamin D such as an increase in calcium and phosphate may favor the development of vascular calcifications while other functions such as modulation of an inflammatory response may have a preventive effect [9, 10].
The Mechanisms of Vascular Calcification in CKD

The mechanisms involved in the development of vascular calcification are being progressively elucidated through exponentially increasing the number of in vitro and in vivo studies. A detailed description of this process is beyond the scope of this review (recently revised in Sage et al. [11]). Briefly, vascular calcification is currently accepted as an actively regulated process similar to bone formation involving many complex cell-related and chemical events involving the active participation of a number of calcification inducers/promoters and inhibitors (table 1). Bone proteins are expressed in arterial tissue undergoing calcification; this reflects the changes in the phenotype of vascular smooth muscle cells (VSMCs) into osteoblast-like cells which produce calcification-regulating proteins [12–15]. This phenotypic change can be triggered by a number of different situations such as low levels of estrogens, vitamin K, inflammation, oxidative stress, and dyslipidemia. Thus, the vascular wall has the potential to make bone, but only under certain pathological circumstances, i.e. uremia, diabetes and aging, does this potential become operational.

Through the course of vascular calcification, calcium phosphate-enriched vesicles are released from viable and apoptotic VSMCs, which serve as nidi for extracellular crystal initiation [16, 17]. Of note, Sage et al. [18] have recently shown that the calcium phosphate nanocrystals, formed in the presence of high levels of inorganic phosphate, may regulate cell differentiation and calcification gene expression independently of free inorganic phosphate. These authors suggest that the nanoparticles were endocytosed producing a release of calcium into the cytosol that may induce gene expression and apoptosis. Interestingly, Speer et al. [19] have shown that cells with an osteochondrogenic phenotype isolated from calcifying arterial media were reprogrammed to recover smooth muscle cell properties and downregulated osteochondrogenic gene upon culture in medium that favors smooth muscle cell differentiation; in addition, the phenotypic switch of the restored smooth muscle cells to the osteochondrogenic state was re-induced by inorganic phosphate. These authors suggest that the nanoparticles were endocytosed producing a release of calcium into the cytosol that may induce gene expression and apoptosis. Interestingly, Speer et al. [19] have shown that cells with an osteochondrogenic phenotype isolated from calcifying arterial media were reprogrammed to recover smooth muscle cell properties and downregulated osteochondrogenic gene upon culture in medium that favors smooth muscle cell differentiation; in addition, the phenotypic switch of the restored smooth muscle cells to the osteochondrogenic state was re-induced by inorganic phosphate. These authors suggest that the nanoparticles were endocytosed producing a release of calcium into the cytosol that may induce gene expression and apoptosis. Interestingly, Speer et al. [19] have shown that cells with an osteochondrogenic phenotype isolated from calcifying arterial media were reprogrammed to recover smooth muscle cell properties and downregulated osteochondrogenic gene upon culture in medium that favors smooth muscle cell differentiation; in addition, the phenotypic switch of the restored smooth muscle cells to the osteochondrogenic state was re-induced by inorganic phosphate. These authors suggest that the nanoparticles were endocytosed producing a release of calcium into the cytosol that may induce gene expression and apoptosis.

Osteogenic transformation is accompanied by the increased expression of molecular mediators of mineralization such as collagen type II, bone sialoprotein, alkaline phosphatase, osteopontin, osteocalcin, bone morphogenetic protein 2 (BMP-2) or receptor activator of NF-κB ligand (RANKL), as well as the increased expression of transcription factors such as Runx2/Cbfa1 and osterix which are specific to osteogenic cells [20] (table 1). On the other hand, the vascular wall and the serum possesses endogenous factors that inhibit vascular calcification [21]; these include matrix Gla protein, fetuin-A, osteoprotegerin, BMP-7, pyrophosphate and others which ordinarily restrict biomineralization to skeletal bone (table 1). In CKD patients, factors promoting calcification prevail over those protecting against calcification, which are found to be inversely correlated with vascular calcification [22, 23].

The understanding of the role of the known and novel pro- and anticalcificant factors is presently attracting the attention as they might be used as markers of the process or for therapeutic purposes as targets or treatments. Davies et al. [24] showed that BMP-7 can prevent vascular calcification in CKD in an atherosclerosis mouse model. In a recent study, Kang et al. [25] evaluated the effect of

<table>
<thead>
<tr>
<th>Procalcificant factors</th>
<th>Anticalcificant factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phosphate</td>
<td>Fetuin-A</td>
</tr>
<tr>
<td>Inflammatory factors</td>
<td>Insulin</td>
</tr>
<tr>
<td>Warfarin</td>
<td>Adiponectin</td>
</tr>
<tr>
<td>LDL</td>
<td>FGF-23/klotho</td>
</tr>
<tr>
<td>Glucose</td>
<td>BMP-7</td>
</tr>
<tr>
<td>Oxidative stress</td>
<td>Osteopontin</td>
</tr>
<tr>
<td>Vitamin D</td>
<td>Estrogen</td>
</tr>
<tr>
<td>Leptin</td>
<td>Magnesium</td>
</tr>
<tr>
<td>Elastin fragmentation</td>
<td>NPP-1</td>
</tr>
<tr>
<td>Heat shock protein 70</td>
<td>HDL</td>
</tr>
<tr>
<td>Cathepsin S</td>
<td>Vitamin K</td>
</tr>
<tr>
<td>RANKL/osteoprotegerin</td>
<td>ANK</td>
</tr>
<tr>
<td>BMP-2</td>
<td>IGF-1</td>
</tr>
<tr>
<td>BMP-4</td>
<td>PTH</td>
</tr>
<tr>
<td>Calcium</td>
<td>PTHrP</td>
</tr>
<tr>
<td>Mxs2</td>
<td>Pyrophosphate</td>
</tr>
<tr>
<td>Osteocalcin</td>
<td></td>
</tr>
<tr>
<td>Runx2/Cbfa1</td>
<td></td>
</tr>
<tr>
<td>Uremic toxins</td>
<td></td>
</tr>
<tr>
<td>Alkaline phosphatase</td>
<td></td>
</tr>
<tr>
<td>Osterix</td>
<td></td>
</tr>
<tr>
<td>Sox9</td>
<td></td>
</tr>
<tr>
<td>Collagen</td>
<td></td>
</tr>
</tbody>
</table>

BMP = Bone morphogenetic protein; FGF-23 = fibroblast growth factor 23; LDL = low-density lipoprotein; HDL = high-density lipoprotein; RANKL = receptor activator of NF-κB ligand; NPP-1 = pyrophosphatase/phosphodiesterase; PTH = parathyroid hormone; PTHrP = PTH-related peptide; IGF-1 = insulin-like growth factor-1; ANK = transmembrane protein.
Vitamin D and Vascular Calcification in Chronic Kidney Disease

phosphate, a Key Factor in Vascular Calcification

Accumulation of phosphate is increasingly adopting a central role in the generation of vascular calcification associated with uremia [15]. This key effect has been demonstrated in in vitro studies, in which the elevation of P concentration in the medium induces a phenotypic change of VSMCs into osteoblast-like cells and a parallel increase in calcification [28, 29]; however, the mechanism governing this is not yet clear. Jono et al. [30] reported that high extracellular P concentrations induce phosphate influx into cytoplasm via the activation of the sodium-dependent phosphate co-transporter (Pit-1). Thus, phosphate may initiate calcification by increasing the activity of Pit-1, and the increased intracellular P leads to the upregulation of osteogenic genes responsible for the phenotypic transformation of the VSMCs such as Runx2, osteocalcin, and alkaline phosphatase and, eventually, for the formation of mineralization-competent extracellular matrix. In addition, increased Pit-1 in matrix vesicles promotes P loading of matrix vesicles, favoring the nucleation of mineral within the extracellular matrix [15]. However, very recently, Villa-Bellosta et al. [31, 32] have shown that the effect of phosphate on vascular calcification may be independent of Pit-1 activity. Thus it is possible that high extracellular phosphate may initiate osteogenic transformation and calcification through the production of calcium-phosphate crystals. Prosdocimo et al. [33] have recently shown that increased cAMP signaling and elevated extracellular inorganic phosphate act synergistically to induce calcification, which is correlated with a progressive reduction in extracellular pyrophosphate. In an in vitro model of VSMCs, we found that high phosphate concentration (3.3 mmol/l) in the medium was associated with increased DNA methyltransferase activity and methylation of the promoter region of the smooth muscle cell-specific protein SM22α (fig. 1). This was accompanied by loss of the SM22α, gain of the osteoblast transcription factor Cbfa1, and increased alkaline phos-

Fig. 1. Schematic representation of the effect of high phosphate levels on VSMC calcification.
phatase activity with the subsequent in vitro calcification [34]. Taking together, these results advocate that the prevention of vascular calcifications requires strict control of phosphate levels in the uremic patients.

**Vitamin D and Vascular Calcification**

An apparent conflict exists between observational studies that suggest that vitamin D receptor (VDR) activators provide a survival advantage for patients with CKD and other studies showing that a high concentration of calcitriol may contribute to vascular calcification. Circulating concentrations of vitamin D have been shown to be inversely correlated with vascular calcification [24] and several retrospective observational studies demonstrate an association between the administration of active vitamin D derivatives and lower relative risk of mortality in patients with CKD independent of serum Ca, P, and PTH levels [35]. Recently, Drechsler et al. [36] investigated the impact of vitamin D status on cardiovascular outcomes and fatal infections in hemodialysis and found that severe vitamin D deficiency was strongly associated with sudden cardiac death, cardiovascular events and mortality, and there were borderline associations with stroke and fatal infection. Nevertheless, numerous studies have shown that in animal models of uremia, vascular calcification appears to be accelerated by the administration of vitamin D [37–42]. Furthermore, calcitriol given to uremic rats for a short period of days at a high dose (1,000 ng/kg) produces aortic calcifications. Interestingly, in this animal model, these changes were partially reversible several weeks after discontinuation of calcitriol administration [38]. Recently, Zebger et al. [43] observed that a high-dose calcitriol treatment induced an osteoblastic phenotype in VSMCs. This was associated with upregulation of proteins involved in mineralization and calcium transport such as osteopontin, osteocalcin, bone sialoprotein, transient receptor potential vanilloid calcium channel 6, calbindin D9K, as well as the osteogenic transcription factor osterix.

Some of the actions of vitamin D, mainly those related to the regulation of mineral metabolism, may favor vascular calcification while other effects of the vitamin D system, such as the regulation of the cell cycle and modulation of the inflammatory response, may protect the vessels from vascular calcification. Excess of calcitriol increases intestinal absorption of phosphate causing hyperphosphatemia which induces vascular calcification. The fibroblast growth factor 23 (FGF-23) null mouse model illustrates that the concomitant increase in phosphate and calcitriol results in vascular calcification. FGF-23 decreases serum phosphate concentration by inducing phosphaturia and decreases calcitriol by inhibiting renal 1α-hydroxylase activity. The lack of FGF-23 results in hypophosphatemia and excess of calcitriol. These rodents develop vascular calcification and survive only few weeks. Thus, the combination of high phosphate and high calcitriol produces vascular calcification (fig. 2). This is similar to what is seen in some dialysis patients with uncon-
trolled phosphate and receiving excess amount of calcitriol to control secondary hyperparathyroidism. In a study by Stubbs et al. [44], FGF-23 null mice were fed a regular diet and diets deficient in P or in vitamin D. In a low P diet, the serum levels of P were reduced but calcitriol levels remained high and these mice did not develop vascular calcification. In FGF-23 null mice, a vitamin-D-deficient diet caused a decrease in the serum calcitriol level but serum P remained high and vascular calcification was present. Thus, vitamin D excess may not induce calcification if phosphate is controlled.

In our laboratory, 5/6Nx rats on a high P diet for a couple of weeks showed moderate vascular calcification; the administration of calcitriol markedly increased vascular calcification [45]. However, the reduction to a half the dietary content of P prevented vascular calcification despite the same dose of calcitriol. Again high P is a key factor in vascular calcification associated with vitamin D administration.

As VSMCs express the VDR [46], it is reasonable to assume that calcitriol, the main ligand for the VDR, has a direct effect on VSMCs and vascular calcification. Nevertheless, a direct effect of vitamin D on vascular calcification is difficult to evaluate in vivo since the administration of calcitriol results in hypercalcemia, hyperphosphatemia, and an increase in Ca × P product. Mizobuchi et al. [47] administrated 0.04 μg/kg of calcitriol intraperitoneally three times a week for 1 month; this dose of calcitriol produced medial layer calcification, but it was associated with a marked increase in serum Ca, P, and the Ca × P product. However, a study by Koleganova et al. [48] showed that a moderate dose of calcitriol produced vascular calcification in both sham and uremic rats. This effect was observed despite no changes in serum levels of calcium and phosphate suggesting that calcitriol may directly affect vascular calcification. In vitro studies have been performed to evaluate a direct effect of calcitriol on VSMC calcification. Jono et al. [49] showed that in VSMCs cultured with high P, the addition of an increasing concentration of calcitriol produced a dose-dependent increase in calcium deposition. This effect of high concentration of calcitriol is associated with an increase in the RANKL/osteoprotegerin ratio [37] and the expression of osteopontin [50]. Osteoprotegerin has recently been shown as an independent predictor of mortality in CKD patients and proposed as a potential early biomarker for vascular calcification [51].

Calcitriol could induce vascular calcification through effects on bone metabolism. In patients undergoing dialysis, the low-turnover bone disease derived from low serum PTH levels is associated with vascular calcification [52]. Oversuppression of bone remodeling by calcitriol may cause vascular calcification through an imbalance of Ca and P influx into the bone [53]. Mathew et al. [54] studied the effects of the VDR activators calcitriol and paricalcitol on aortic calcification in an LDLR−/− mouse model with CKD. Low doses of calcitriol decreased vascular calcification and this was associated with increased bone activity. These results suggest that the administration of a low dose of vitamin D analogs may protect from vascular calcification by increasing the bone activity with the incorporation of mineral to bone.

The dualistic role of vitamin D in vascular calcification is illustrated by the work of Shroff et al. [55], who have shown in pediatric dialysis patients that both low and high calcitriol levels were associated with increases in vascular calcification. Both the carotid intima-media thickness and calcification were increased in those patients with a low as well as with a high serum concentration of calcitriol. Interestingly, the presence of calcifications was associated with increased CRP levels, a marker of inflammation, and there was a tight negative exponential correlation between CRP and serum calcitriol levels. This clinical report shows an association between vascular calcification, calcitriol levels and inflammatory parameters.

Vitamin D Analogs and Vascular Calcification

The risk of inducing hypercalcemia and hyperphosphatemia with the administration of high doses of calcitriol in CKD patients led to the search for analogs that retain the effect of calcitriol on parathyroid glands while lacking the hypercalcemic and hyperphosphatemic effects [56]. New vitamin D compounds already in clinical use, which have an improved side effect profile, are limited to paricalcitol, 22-oxacalcitriol, and doxercalciferol [57].

Different experimental studies have shown that the vitamin D analog paricalcitol produces less calcification than calcitriol. This may be one of the reasons why Teng et al. [58] showed improved survival in patients treated with paricalcitol as compared with calcitriol. Mizobuchi et al. [39] showed that whereas administration of calcitriol and doxercalciferol induced vascular calcifications in uremic rats, equivalent doses of paricalcitol did not produce vascular calcification. This benefit of paricalcitol could have been explained by a less calcemic and phosphatemic effect of paricalcitol as compared with the oth-
er analogs. However, an increase in the dose of paricalci-
tol, enough to produce hyperphosphatemia and hyper-
calcemia, did not produce vascular calcification. Thus a
direct protective effect of paricalcitol on vascular calcifi-
cation was suggested. In different experiments, control
and uremic rats were treated with vehicle, calcitriol, pari-
calcitol, calcimimetic or the combination of calcimimetic
plus calcitriol or paricalcitol. Equivalent doses of pari-
calcitol produced less calcification than calcitriol. The
addition of calcimimetic to paricalcitol produced total
prevention of vascular calcification and excellent control
of secondary hyperparathyroidism [59]. Cardús et al. [37]
showed in vivo and in vitro that calcitriol, but not pari-
calcitol, increased calcification of VSMCs independently
of the levels of calcium and phosphate. Of note, the dif-
ferent effects on calcification were accompanied by a
differential activation of RANKL, which has been shown
to induce vascular calcification by increasing the expres-
sion of BMP-4 [60]. Noonan et al. [61] evaluated in uremic
rats with established secondary hyperparathyroidism the
differential effects of paricalcitol and doxercalciferol on
aortic calcification. Both of them produced a decrease in
PTH and there were no differences in aortic calcium and
phosphorus contents at the end of 6 weeks among sham,
uremic and paricalcitol-treated uremic rats. However, in
doxercalciferol-treated uremic rats, there was a signifi-
cant increase in aortic calcium and P contents. Hirata et
al. [40] assessed the effect of maxacalcitol, another vita-
min D analog, on vascular calcification. They observed
that maxacalcitol not only reduced PTH levels, but it also
decreased calcium content in the aorta as compared to
calcitriol-treated animals, despite the fact that both cal-
citriol and maxacalcitol induced a similar increase in
Ca × P product. Additionally, in a recent study, Sugiu-
ra et al. [62] showed in a retrospective cohort study with
predialysis patients with CKD that the oral administra-
tion of alfacalcidol was associated with reduced risk of
cardiopulmonary disease. Interestingly, the beneficial effect
of VDR compounds on vascular calcification may be me-
diated via other cell types. Li et al. [7] found that co-cul-
ture with macrophages promoted smooth muscle cell cal-
cification, and this was inhibited by calcitriol and pari-
calcitol treatment; osteopontin was identified as candi-
date paracrine factor for the protective effect.

All these studies suggest differential effects of vitamin
D analogs on vascular calcification, that may be explained
by distinct effects on target genes involved in the patho-
genesis of cardiovascular remodeling and arterial calcifi-
cations. It has been demonstrated that the activation of
the VDR by paricalcitol or 22-oxacalcitriol recruits dif-
f erent coactivators from those recruited by calcitriol [63].
Different cell events after activation of the same VDR by the
different analogs may explain why some analogs may
not promote vascular calcification.

Finally, though the current treatment of vascular cal-
cification is preventive and based on reducing hyper-
phosphatemia and hypercalcemia, a new approach is the
search for specific treatments for vascular calcification.
All the processes involved in the development of vascular
calcification, mainly the systemic and local factors that
can promote or inhibit vascular calcification, are poten-
tial therapeutic targets which are just being evaluated (see
O’Neill and Lomashvili [56] for a recent revision).

Conclusions

The use of high doses of vitamin D with ensuing hy-
perphosphatemia and hypercalcemia may cause vascular
calcification. Clinical and experimental work suggests
that reasonable doses of vitamin D may prevent vascular
calcification through modulation of the inflammatory
response. Furthermore, clinical observations demon-
strate that vitamin D analogs, such as paricalcitol, pro-
vide a survival benefit for patients with CKD. In vitro and
in vivo studies demonstrate that the calcifications in-
duced by high concentrations of calcitriol are not ob-
erved with the use of paricalcitol and other analogs.
However, no clinical prospective study has been per-
formed to demonstrate a beneficial effect of paricalcitol
on vascular calcification.

Acknowledgments

This study was supported by the Instituto Carlos III (FIS 07-
0287, FIS 07/0315, Red renal RD 06/0016/0007) and Junta de An-
dalucía (0039/07, 0127/08, 0132/10). Y.A. is a senior researcher
supported by the Fundacion Progreso y Salud, Consejeria de
Salud (Junta de Andalucía). We thank Dr. Antonio Canalejo for
helpful suggestions.

Disclosure Statement

None.
References


